-
Most Recent
Search Results
240 results for akns
AON Stock Earnings: Aon Misses EPS, Beats Revenue for Q2 2024
AON stock results show that Aon missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
AON Stock Earnings: Aon Misses EPS, Misses Revenue for Q1 2024
AON stock results show that Aon missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Allergan Plc: Will the Downtrend Continue for AGN Stock?
Despite chatter of a biotech acquisition and earnings Monday morning, the options market in AGN stock suggests normal event risk next week.
Is AstraZeneca a Buy After Pfizer Breakup? 3 Pros, 3 Cons
AZN turned down Pfizer’s offer — a premium of more than 40% for AZN stock — sending shares down more than 10%. But is that…
Earnings Visibility Make AstraZeneca (AZN) a Buy
AstraZeneca Plc (NYSE:AZN) is a $83.3 billion in market value constituent of the Pharmaceuticals GICS industry group where the ranking for AZN by Portfolio Grader…
Quant Score Restricts AstraZeneca (AZN) Rating
AstraZeneca Plc (NYSE:AZN) is a component of the 135 company Pharmaceuticals GICS industry group, which is a segment of the 783 company GICS Health Care…
Allergan (AGN) a Sell on Sinking Industry Group Rank
Allergan Inc (NYSE:AGN) is ranked as a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier’s investing methodology. This represents no change from…
The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger
AstraZeneca’s profits are poised to accelerate, but investors should wait for AZN stock to break out of its range before buying the shares.
Take Profits in Ascena Retail Group Now (ASNA, ANN)
Ann Inc. is being purchased by Ascena Retail Group for more than $2.2 billion. ANN shareholders getting a great deal, but ASNA investors don’t appear…
AZN, PFE: Pfizer Confirms Interest in Buying AstraZeneca
Pfizer says it has approached AstraZeneca about a possible $100 billion merger deal, sending AZN stock surging in Monday trading.
Allergan (AGN) a Strong Sell at $148.73
The Strong Sell for Allergan (AGN) this week is based on the most recent news, and relative pricing of its shares.
At $159.86, Allergan (AGN) a Strong Sell
The Strong Sell for Allergan (AGN) this week is based on the latest comparative pricing of its shares and news.
AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. With unique fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000…
AstraZeneca’s (AZN) Stock Has Sell Ranking Reaffirmed
Currently, AstraZeneca Plc (NYSE:AZN) has a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier’s investing methodology. AZN has maintained this ranking for…
Ann Inc: Get Dressed for Market-Beating Success
Retailer stocks are holding up well year-to-date, among them women’s apparel company Ann Inc, whose stock looks set to rally further.
AstraZeneca’s Big Fat Dividend. Play it Safe
The strongest leadership in the market this year is coming from the drug sector. Let’s take a quick look at one: AstraZeneca (AZN).
This Week, Accenture (ACN) drops to a Buy
Accenture (ACN) drops to a Buy this week based on the most current news, and comparative pricing of its shares.
Accenture Plc (ACN) Gets an Upgrade, But It’s Not a Buy
Business is good at Accenture plc, but ACN stock looks like it has gotten ahead of itself in terms of valuation.
Allergan: Why the Earnings Rally Is WAY Overdone for AGN Stock
Allergan (AGN) stock is soaring on Tuesday after an earnings beat and announcement of a huge stock buyback. But the rally is WAY overdone.
Two-Part Trade for Accenture Earnings (ACN)
Simultaneously buying a call and a put hedges your risk with ACN earnings today.
Hold Rating for AstraZeneca (AZN) Retained
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Hold. With exclusive fundamental and quantitative analytical tools developed by Louis Navellier, this analytical tool evaluates nearly…
Strong Sell for Allergan (AGN) This Week
At $150.69, Allergan (AGN) a Strong Sell based on the most current stock market ratings, and comparative pricing of its shares.
Allergan Stock Is Worth a Look for Long-Term Investors
The short-term outlook on AGN stock is messy due to drug pricing issues. But the long-term outlook remains promising – thanks to the company’s wide…
4 – 10 of 240 results
